Royalty Monetization

Through royalty monetization, we help you leverage future cash flows - unlocking the funds you need today without giving up equity.

The innovative approach provides a strategic pathway to fuel growth, drive development, and mitigate the uncertainty of future revenues.

Royalty monetization

There are many recent transactions showcasing the value of royalty monetization.

Lastest posts

View all posts->

August

2026

- release at

CET

Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision

As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.

July

2026

- release at

CET

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

NEW YORK, NY, July 22, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.

March

2026

- release at

CET

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

NEW YORK, NY, and VANCOUVER, BC, March 2, 2026 – Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).

View all posts->

Unlock Growth through Royalty Monetization

Get your free royalty value estimate

Through royalty monetization, we help you leverage future cash flows - unlocking the funds you need today without giving up equity.